M6495

DRUG2 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

HealthyOsteoarthritis, Knee

Phase 1

First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers

CompletedNCT03224702

Merck KGaA, Darmstadt, GermanyHealthy

Start: 2017-09-04End: 2018-08-06Updated: 2019-05-02

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

CompletedNCT03583346

Merck KGaA, Darmstadt, GermanyOsteoarthritis, Knee

Start: 2018-08-23End: 2019-07-31Updated: 2020-01-23